Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report

Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report Platinum-based chemotherapy regimens are often recommended for patients with unresectable thymic carcinoma. In more than 60 cases, however, the systemic chemotherapy provides little benefit. In this report, we described a case of advanced KIT- and VEGF-positive thymic carcinoma with liver and lung metastasis. The patient, a 46-year-old man, exhibited a resistance to cisplatin-based chemotherapy, but responded to the treatment with sorafenib, a molecular target-based therapy. After 4 months of sorafenib therapy, his lung and liver metastases as well as the mediastinal tumor shrank dramatically. Moreover, the tumors showed stable disease for at least 9 months. To the best of our knowledge, it is the first report about a response of advanced thymic carcinoma to sorafenib. The preliminary study suggested that molecular target-based therapy could be an alternative treatment to those chemotherapy-refractory patients. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Medical Oncology Springer Journals

Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report

Loading next page...
 
/lp/springer-journals/response-to-sorafenib-in-cisplatin-resistant-thymic-carcinoma-a-case-bRjHdSqo0t

References (19)

Publisher
Springer Journals
Copyright
Copyright © 2008 by Humana Press Inc.
Subject
Medicine & Public Health; Internal Medicine ; Pathology ; Hematology; Oncology
ISSN
1357-0560
eISSN
1559-131X
DOI
10.1007/s12032-008-9100-0
pmid
18846437
Publisher site
See Article on Publisher Site

Abstract

Platinum-based chemotherapy regimens are often recommended for patients with unresectable thymic carcinoma. In more than 60 cases, however, the systemic chemotherapy provides little benefit. In this report, we described a case of advanced KIT- and VEGF-positive thymic carcinoma with liver and lung metastasis. The patient, a 46-year-old man, exhibited a resistance to cisplatin-based chemotherapy, but responded to the treatment with sorafenib, a molecular target-based therapy. After 4 months of sorafenib therapy, his lung and liver metastases as well as the mediastinal tumor shrank dramatically. Moreover, the tumors showed stable disease for at least 9 months. To the best of our knowledge, it is the first report about a response of advanced thymic carcinoma to sorafenib. The preliminary study suggested that molecular target-based therapy could be an alternative treatment to those chemotherapy-refractory patients.

Journal

Medical OncologySpringer Journals

Published: Oct 10, 2008

There are no references for this article.